Sg Americas Securities, LLC Tcr2 Therapeutics Inc. Transaction History

Sg Americas Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$2.4 - $4.71 $54,165 - $106,299	-22,569 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$4.58 - $8.34 $16,107 - $29,331	-3,517 Reduced 13.48%	22,569 $105,000
Q3 2021 Nov 01, 2021	BUY	$8.44 - $18.35 $98,832 - $214,878	11,710 Added 81.46%	26,086 $222,000
Q2 2021 Aug 12, 2021	BUY	$16.41 - $24.71 $69,955 - $105,338	4,263 Added 42.15%	14,376 $236,000
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $133,692 - $223,499	6,560 Added 184.63%	10,113 $223,000
Q4 2020 Feb 04, 2021	BUY	$19.0 - $32.63 $67,507 - $115,934	3,553 New	3,553 $110,000
Q3 2020 Nov 09, 2020	SELL	$13.1 - $20.69 $116,721 - $184,347	-8,910 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$6.51 - $16.85 $58,004 - $150,133	8,910 New	8,910 $137,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.